Loading…
KAOLIN AND MORPHINE MIXTURE is a brand name for Morphine. The medicine, its uses, side effects and dosage are the same regardless of brand.
Used for: For relief of the symptoms of diarrhoea and upset stomachs in adults and children over 12 years.
Verbatim from this product's MHRA label. Tap a section to expand.
Oral.
Recommended doses:
Adults and children over 12 years: Two 5ml spoonfuls.
Children under 12 years:
Not recommended for children under 12 years.
Directions for use:
Shake the bottle.
Dosage schedule:
The dose may be repeated 3 times daily or as directed.
The sodium hydrogen carbonate in this product may cause stomach cramps and flatulence. Morphine, whilst only present in a low concentration, may theoretically cause nausea, vomiting, constipation, drowsiness and confusion. Prolonged use may lead to tolerance and dependence.
Although there are qualitative and quantitative differences in side effects for the opioid analgesics, other recognised possible side effects include: difficulty with micturition; ureteric or biliary spasm; dry mouth; sweating; headache; facial flushing; vertigo; bradycardia, tachycardia or palpitation; postural hypotension; hypothermia; hallucinations, dysphoria or mood changes; miosis; decreased libido or potency; rashes, urticaria, pruritis and opioid-induced hyperalgesia (OIH).
Skin and subcutaneous tissue disorders:
Acute generalised exanthematous pustulosis (AGEP).
Respiratory disorders:
Central sleep apnoea syndrome.
Gastrointestinal disorders:
Pancreatitis.
Hepatobiliary disorders:
Spasm of sphincter of Oddi. Drug dependence Repeated use of Kaolin and Morphine Mixture can lead to drug dependence, even at therapeutic doses. 4). Reporting of suspected adverse reactions Reporting suspected adverse reactions after authorisation of the medicinal product is important.
It allows continued monitoring of the benefit/risk balance of the medicinal product. uk/yellowcard or search for “MHRA Yellow Card” in the Google Play or Apple App Store.
As this product contains sodium hydrogen carbonate, it should not be administered to patients with metabolic or respiratory alkalosis, hypocalcaemia or hypochlorhydria, and should be administered with caution in patients with congestive heart failure, renal impairment, cirrhosis of the liver, hypertension and to patients receiving corticosteroids.
Whilst this product only contains a small amount of morphine, it should (as with other morphine-containing preparations) be used with care in the elderly or debilitated (when the dose should be reduced), in prostatic hypertrophy, in hypotension, in hypothyroidism and where there is reduced respiratory reserve (avoid use during an asthma attack), and should not be given if paralytic ileus is likely to occur.
Sleep-related breathing disorders Opioids can cause sleep-related breathing disorders including central sleep apnoea (CSA) and sleep-related hypoxemia. Opioid use increases the risk of CSA in a dose-dependent fashion. In patients who present with CSA, consider decreasing the total opioid dosage.
Severe cutaneous adverse reactions (SCARs) Acute generalized exanthematous pustulosis (AGEP), which can be life-threatening or fatal, has been reported in association with morphine treatment. Most of these reactions occurred within the first 10 days of treatment.
Patients should be informed about the signs and symptoms of AGEP and advised to seek medical care if they experience such symptoms. If signs and symptoms suggestive of these skin reactions appear, morphine should be withdrawn and an alternative treatment considered.
Hepatobiliary disorders Morphine may cause dysfunction and spasm of the sphincter of Oddi, thus raising intrabiliary pressure and increasing the risk of biliary tract symptoms and pancreatitis. Opioid Use Disorder (abuse and dependence) Tolerance and physical and/or psychological dependence may develop upon repeated administration of opioids such as Kaolin and Morphine Mixture.
3 Contra-indications Kaolin is contraindicated in intestinal obstruction. Whilst this product only contains a small amount of morphine, theoretically it should be contraindicated in the same conditions as other morphine-containing preparations.
These conditions include respiratory depression, obstructive airways disease, known morphine sensitivity, acute hepatic disease, acute alcoholism, head injuries, coma, convulsive disorders, where intracranial pressure is raised, and in concurrent administration with monoamine oxidase inhibitors or within 2 weeks of discontinuation of their use.
1.
Not medical advice. Always read the patient information leaflet and follow your prescriber or pharmacist.
Other brands of Morphine in United Kingdom.
Know a brand we are missing in United Kingdom? Suggest a brand →
Brand names are compiled from public regulatory records for active-ingredient mapping only. Drugvu is not affiliated with any manufacturer. This is not medical advice.
Repeated use of Kaolin and Morphine Mixture can lead to Opioid Use Disorder (OUD). A higher dose and longer duration of opioid treatment, can increase the risk of developing OUD. Abuse or intentional misuse of Kaolin and Morphine Mixture may result in overdose and/or death.
The risk of developing OUD is increased in patients with a personal or a family history (parents or siblings) of substance use disorders (including alcohol use disorder), in current tobacco users or in patients with a personal history of other mental health disorders (eg.
major depression, anxiety and personality disorders). Before and during treatment with Kaolin and Morphine Mixture the patient should be informed about the risks and signs of OUD. If these signs occur, patients should be advised to contact their physician or pharmacist.
g. too early requests for refills). This includes the review of concomitant opioids and psycho-active drugs (like benzodiazepines). For patients with signs and symptoms of OUD, consultation with an addiction specialist should be considered.
Risk from concomitant use of sedative medicines such as benzodiazepines or related drugs: Concomitant use of morphine and sedative medicines such as benzodiazepines or related drugs may result in sedation, respiratory depression, coma and death.
Because of these risks, concomitant prescribing with these sedative medicines should be reserved for patients for whom alternative treatment options are not possible. If a decision is made to prescribe this medicine concomitantly with sedative medicines, the lowest effective dose should be used, and the duration of treatment should be as short as possible.
The patients should be followed closely for signs and symptoms of respiratory depression and sedation. 5). 5). Patients with rare hereditary problems of fructose intolerance, glucose-galactose malabsorption should not take this medicine.
This product contains 70mg fructose in each 10ml dose. The additive effect of concomitantly administered products containing fructose (or sorbitol) and dietary intake of fructose (or sorbitol) should be taken into account. 00175% w/v.
This product contains sucrose. Patients with rare hereditary problems of fructose intolerance, glucose-galactose malabsorption or sucrase-isomaltase insufficiency should not take this medicine. 38% w/v. The amount in 10ml is equivalent to less than 1ml of beer and 1ml of wine.
The small amount of alcohol in this medicine will have no noticeable effects. 4% of the WHO recommended maximum daily intake of 2g sodium for an adult. 05μg benzyl alcohol per 10ml dose, which may cause allergic reactions. High volumes should be used with caution and only if necessary, especially in subjects with liver or kidney impairment because of the risk of accumulation and toxicity (metabolic acidosis).
This product contains sodium methyl and sodium propyl parahydroxybenzoates (E219 and E217 respectively) which may cause allergic reactions (possibly delayed).
The following warnings and precautions appear on the labels:
Do not take more medicine than the label tells you to. Keep out of the sight and reach of children Do not take with alcoholic or hot drinks.